The stock price of Aligos Therapeutics Inc (NASDAQ: ALGS) has plunged by -27.97 when compared to previous closing price of 14.16, but the company has seen a -27.30% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-19 that SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects.
Is It Worth Investing in Aligos Therapeutics Inc (NASDAQ: ALGS) Right Now?
The stock has a 36-month beta value of 2.15. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALGS is 2.25M, and at present, short sellers hold a 0.66% of that float. On September 19, 2024, the average trading volume of ALGS was 39.24K shares.
ALGS’s Market Performance
ALGS stock saw a decrease of -27.30% in the past week, with a monthly decline of -29.56% and a quarterly a decrease of -1.95%. The volatility ratio for the week is 11.57%, and the volatility levels for the last 30 days are 12.09% for Aligos Therapeutics Inc (ALGS). The simple moving average for the last 20 days is -25.42% for ALGS stock, with a simple moving average of -39.47% for the last 200 days.
Analysts’ Opinion of ALGS
Many brokerage firms have already submitted their reports for ALGS stocks, with H.C. Wainwright repeating the rating for ALGS by listing it as a “Buy.” The predicted price for ALGS in the upcoming period, according to H.C. Wainwright is $75 based on the research report published on August 19, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ALGS reach a price target of $3, previously predicting the price at $2. The rating they have provided for ALGS stocks is “Overweight” according to the report published on January 06th, 2023.
Jefferies gave a rating of “Buy” to ALGS, setting the target price at $3 in the report published on January 06th of the previous year.
ALGS Trading at -23.36% from the 50-Day Moving Average
After a stumble in the market that brought ALGS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.00% of loss for the given period.
Volatility was left at 12.09%, however, over the last 30 days, the volatility rate increased by 11.57%, as shares sank -24.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.63% lower at present.
During the last 5 trading sessions, ALGS fell by -26.09%, which changed the moving average for the period of 200-days by -40.84% in comparison to the 20-day moving average, which settled at $13.51. In addition, Aligos Therapeutics Inc saw -38.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALGS starting from Nuechterlein Carole, who purchase 7,933,601 shares at the price of $0.76 back on Oct 25 ’23. After this action, Nuechterlein Carole now owns 11,025,941 shares of Aligos Therapeutics Inc, valued at $6,004,149 using the latest closing price.
Stock Fundamentals for ALGS
Current profitability levels for the company are sitting at:
- -11.74 for the present operating margin
- 0.66 for the gross margin
The net margin for Aligos Therapeutics Inc stands at -9.51. The total capital return value is set at -1.1. Equity return is now at value -110.67, with -70.47 for asset returns.
Based on Aligos Therapeutics Inc (ALGS), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -8.66. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is 6.78.
Currently, EBITDA for the company is -84.36 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of 3.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.23.
Conclusion
To sum up, Aligos Therapeutics Inc (ALGS) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
